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Abstract
Background: The functional equilibrium between natural regulatory T cells (Treg) and effector T cells can affect the issue of
numerous infections. In unvaccinated mice, the influence of Treg in the control of primary infection with mycobacteria
remains controversial.
Methodology: Here, we evaluated the role of Treg during prophylactic vaccination with Mycobacterium bovis BCG (Bacillus
Calmette-Gue ´rin) on the induction of T cell responses and on the protective effect against subsequent M. tuberculosis
challenge in mice.
Principal Findings: We demonstrated that, subsequent to BCG injection, Treg were recruited to the draining lymph nodes
and negatively control anti-mycobacterial CD4
+ — but not CD8
+ — T-cell responses. Treatment of BCG-immunized mice
with an anti-CD25 mAb (PC61) induced an increase IFN-c response against both subdominant and immunodominant
regions of the protective immunogen TB10.4. In Treg-attenuated, BCG-immunized mice, which were then infected with M.
tuberculosis, the lung mycobacterial load was significantly, albeit moderately, reduced compared to the control mice.
Conclusions: Our results provide the first demonstration that attenuation of Treg subset concomitant to BCG vaccination
has a positive, yet limited, impact on the protective capacity of this vaccine against infection with M. tuberculosis. Thus, for
rational design of improved BCG, it should be considered that, although the action of Treg does not represent the major
cause of the limited efficiency of BCG, the impact of this cell population on the subsequent control of M. tuberculosis growth
is significant and measurable.
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Introduction
The only vaccine available against infection with Mycobacterium
tuberculosis is the live attenuated M. bovis BCG (Bacillus Calmette-
Gue ´rin). With more than three billion of doses injected, BCG is
the most used vaccine in the world, although its efficiency is highly
variable. Even though, in non-endemic zones, BCG is efficient up
to 80% against disseminated infections with M. tuberculosis, this
vaccine is not able to protect efficiently against the adult
pulmonary tuberculosis in endemic zones. Moreover, the resur-
gence of tuberculosis in immuno-compromised individuals and the
rapid expansion of multi-drug resistant and extensively drug
resistant tuberculosis [1] reinforce the need of fundamental
understanding of the variability and the limited efficiency of
BCG for a better rational design of new strategies of anti-
tuberculosis vaccines [2].
Variability in the efficiency of BCG against infection with M.
tuberculosis can be explained by differences in vaccination protocols
and in BCG strains used in different areas of the world and human
genetic factors, predisposing individuals to develop an active
tuberculosis [3,4]. Moreover, this variability can also be due, in
endemic zones, to pre-exposure to environmental mycobacteria,
such as M. avium, which could induce immune responses against
antigens shared with BCG. The resulted immune cross-recogni-
tion may decrease the persistence of subsequently injected BCG
and may lead to variable protective efficiency [5,6]. On the other
hand, the limited efficiency of BCG against infection with M.
tuberculosis can be explained by the following hypotheses. (i)
Deletion of genes coding for protective immunogens in BCG and/
or over attenuation of BCG, due to the loss of genetic Regions of
Differences (RD) [7,8] could explain the weak efficiency of BCG.
This hypothesis has been confirmed by genetic reintroduction of
RD1 into the BCG Pasteur strain [9,10]. The resulted BCG::RD1
is able to induce marked Th1 responses to M. tuberculosis-specific
antigens, i.e., Early Secreted Antigenic Target, 6 kDa (ESAT-6
3)
and Culture Filtrate Protein, 10 kDa. It displays an increased
virulence and persistence, which are in direct correlation with the
increased protective capacity of this vaccine candidate against M.
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Th1 cells by BCG immunization, intracellular mycobacteria
sequestered within granuloma, may be inaccessible to these
effector T cells. (iii) Finally, subsequent to BCG immunization,
concomitant induction of regulatory T cells (Treg) [12], in parallel
to the induction of anti-mycobacterial T-cell responses, could
reduce the efficiency of the latter in protection against M.
tuberculosis.
During infection, like IL10 and TGF-b, the principal function of
CD4
+ CD25
+ FoxP3
+ Treg is the control of intense inflammation,
induced at the site of infection, to avoid tissue damage. However,
this immune regulation can counteract the function of CD4
+ or
CD8
+ effector T cells and paradoxically dampen the control of
infection. Subsequent to the pioneering work on the role of Treg in
the persistence of Leishmania major in mice [13], it has been shown
that the functional balance between natural Treg and effector T
cells can influence the control of numerous viral, bacterial or
parasitic infections [14].
With respect to the control of primary mycobacterial infections
in unvaccinated mice, the role of Treg remains controversial in the
few works addressing this question. Indeed, Quinn et al. showed
that anti-CD25 mAb treatment in mice has no consequence on the
control of mycobacterial growth [15]. In contrast, when effector T
cells and Treg were adoptively co-transferred, at high Treg/
effector T cells ratio into recipients, Treg were able to significantly
inhibit the action of effector T cells on the control of M. tuberculosis
growth [16]. An improved control of M. tuberculosis infection was
also observed under conditions of total depletion of FoxP3
+ T cells,
giving rise to a substantial polyclonal — but not mycobacteria-
specific — activation of T cells [17]. Besides these discrepancies, it
is important to know whether the prophylactic anti-mycobacterial
vaccination with BCG leads to induction of Treg, with the
potential to influence the T-cell mediated control of subsequent
infection with virulent M. tuberculosis. Here, by use of a standard
mouse model of anti-tuberculosis vaccine assay [18], we studied
the possible recruitment/expansion of Treg in mice immunized
s.c. with BCG or infected with M. tuberculosis via aerosol route. By
modulating the Treg compartment during BCG immunization, we
evaluated the role of these cells on the set up of anti-mycobacterial
CD4
+ or CD8
+ T-cell responses. Finally, in mice immunized with
BCG and treated with anti-CD25 mAb (PC61), we investigated
the T-cell responses at the site of infection and the outcome of M.
tuberculosis infection. Our results show that, during immunization
with BCG, attenuation of Treg function by anti-CD25 mAb
(PC61) treatment, finely tunes anti-mycobacterial Th1 responses
and slightly, yet significantly, improves the protective efficiency of
BCG against infection with M. tuberculosis.
Results
Recruitment/expansion of Treg in lymphoid organs of
BCG-immunized mice
We first analyzed the possible recruitment/expansion of Treg in
the inguinal draining lymph nodes and spleen of BALB/c mice
immunized s.c. with 1610
6 CFU of BCG. At 3 weeks post-
immunization, percentages of CD25
+ FoxP3
+, and also of CD25
2
FoxP3
+, within the CD4
+ T-cell compartment of the inguinal
lymph nodes and of the spleen of BCG-immunized mice
(Figure 1A, top) were comparable to those of age-matched non-
immunized controls (Figure 1A, bottom). However, after s.c.
immunization with BCG, following a 4-week-kinetics study, we
observed that, in the inguinal lymph nodes, despite the non
variable percentage of CD25
+ FoxP3
+ within the CD4
+ T-cell
subset (Figure 1B top, left), the absolute number of these cells
statistically increased (Figure 1B bottom, left), albeit in a
comparable manner to the increase of the number of total lymph
node cells (Figure 1B top, right), or of the number of CD4
+ T cells
(Figure 1B bottom, right). The increased Treg numbers in the
draining lymph nodes may result from their recruitment, local
proliferation/retention or conversion from CD4
+ CD25
2 T cells.
No change was detected in the number of CD4
+ CD25
+ FoxP3
+
cells in the spleen (data not shown). Thus, the size of the Treg
compartment grows proportionally to that of the total cells and of
the CD4
+ T-cell subset in the draining lymph nodes of BCG-
immunized mice.
Treg-mediated negative regulation of anti-mycobacterial
CD4
+ T-cell responses in BCG-immunized mice
To investigate the possible role of Treg on anti-mycobacterial
T-cell responses following BCG immunization, we evaluated IFN-
c CD4
+ T-cell responses of mice immunized by BCG and treated
with anti-CD25 mAb (PC61). As shown in the Figure 2A, mice
received i.p., at day 22 and day 11, PBS or 1 mg of a control rat
Figure 1. Analysis of Treg subset in lymphoid organs of BCG
immunized mice. (A) Percentages of CD25
+ FoxP3
+ cells within the
CD4
+ T-cell subset in inguinal lymph nodes or spleen of BALB/c mice,
untreated or immunized s.c. with 1610
6 CFU of BCG, at three weeks
post-immunization. Results are representative of two independent
experiments. Three mice were analyzed individually and one mouse out
of three is depicted. The numbers indicated in the windows are
percentages of the corresponding cells. (B) Kinetics of recruitment/
expansion of CD25
+ FoxP3
+ T cells in draining lymph nodes of BCG-
immunized mice. Data are percentages of CD25
+ FoxP3
+ cells within the
CD4
+ T-cell subset (left, top), number of CD4
+ CD25
+ FoxP3
+ cells (left,
bottom), total cell number (right, top) or number of CD4
+ T cells (right,
bottom), in the inguinal lymph nodes of PBS-injected or BCG-
immunized mice. Results are means6SD of three mice, studied
individually. *, ** or ***=statistically significant, as determined by
Student’s t test, p,0.05, 0.02 or 0.01, respectively.
doi:10.1371/journal.pone.0002833.g001
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6
CFU of BCG. At day 15 (not shown), as well as at day 21
(Figure 2B), we observed a significant decrease (Anova, p,0.001)
in the percentage of FoxP3
+ within CD4
+ T splenocytes of anti-
CD25-treated mice, compared to their counterparts injected with
PBS or with the control IgG (Figure 2B). Compared to BCG-
vaccinated individuals, unvaccinated mice, treated with PC61
displayed the same range of reduction in percentages of FoxP3
+
within the CD4
+ cell subset (not shown). The partial depletion of
CD4
+ FoxP3
+ T cells in anti-CD25 mAb-treated mice has been
previously described [19–21]. It is noteworthy that such anti-
CD25 mAb treatment with PC61 does allow efficient attenuation
of the Treg function in numerous studies and in different models.
Moreover, this anti-CD25 mAb treatment does not block the
action of activated T cells, as it is reported in many cases, T-cell
responses increased following this treatment [19,22–24].
At day 21, we studied IFN-c CD4
+ T-cell responses of these
mice against TB10.3 (Rv3019c) and TB10.4 (Rv0288) mycobac-
terial immunogens. TB10.3 and TB10.4 are expressed by both
BCG and M. tuberculosis and belong to the immunogenic family of
ESAT-6 proteins [25]. Moreover, TB10.4 has been shown to be a
protective immunogen [26,27]. The frequencies of IFN-c-
producing CD4
+ T splenocytes, specific to MHC-II-restricted
immunodominant epitopes contained in TB10.3:74–88 or
TB10.4:74–88 peptides (Figure 2C), were significantly increased
in anti-CD25-treated mice, compared to the control mice injected
with PBS or with the control IgG. IFN-c responses to these
peptides were only due to CD4
+ T cells, as shown by CD4
+ T-cell
depletion that fully abolished these responses [26]. It is noteworthy
that in anti-CD25 mAb-treated mice, the partial depletion of Treg
corresponds to a loss of 2 to 2.5% of total splenocytes and thus
cannot account for the observed increase in the frequency of IFN-
c-producing splenocytes. Stimulation with the negative control
peptide PV1:103–116 did not reveal any IFN-c producing cells
(not shown).
Based on the fact that responses to all T-cell epitopes are not
affected equally by Treg, it has been suggested that these cells
could modify the profile of T-cell responses to immunodominant
or subdominant regions [28]. We thus sought to determine
whether, under the conditions of Treg attenuation, the profile of
Th1 responses to immunodominant and subdominant regions of a
protective mycobacterial immunogen is modified. To this end, we
evaluated, in individual BCG-immunized mice (n=3), treated with
the control IgG or anti-CD25 (PC61) mAb, as detailed in
Figure 2A, IFN-c production by splenocytes stimulated with
individual overlapping 15-mer peptides, covering the entire
sequence of TB10.4 at a single amino acid step [26]. Unvaccinated
control mice did not produce IFN-c after in vitro stimulation with
these peptides (data not shown, [26]). We previously established
that IFN-c responses detected in these conditions with TB10.4 15-
mer peptides are only due to the CD4
+ T-cell subset [26]. As
shown in Figure 3, TB10.4:7–22 (peptides 7 and 8), TB10.4:14–38
(peptides 14 to 24), TB10.4:37–51 (peptide 37) and TB10.4:40–54
(peptide 40), were very slightly immunogenic in control IgG-
injected mice (Figure 3A). However, these peptides triggered more
intense responses in PC61-treated mice (Figure 3B).
The immunogenic TB10.4:46–65 (peptides 46–51), TB10.4:53–
75 (peptides 53–61) and TB10.4:63–82 (peptides 63–68) regions
triggered detectable responses in control IgG-treated mice
(Figure 3A), but stimulate higher responses in PC61-treated mice
(Figure 3B). In this pepscan assay, no differences were detectable
between the two experimental groups with respect to the
immunogenicity of the C-terminal TB10.4:69–96 (peptides 69–
82) region. This could be due to the high peptide concentration
(20 mg/ml) used in the pepscan assay to detect responses against
weak epitopes. Indeed, compared to their IgG-treated counter-
parts, in the PC61-treated, BCG-immunized mice, higher IFN-c
responses to TB10.4:74–88 were detected by use of ELISPOT
(Figure 2C) or by ELISA in the supernatant of cultures stimulated
with TB10.4:74–88 concentrations, ranging from 0.1 to 100 ng/
ml (not shown). Altogether, these results show that Th1 responses
to both immunodominant and subdominant regions of TB10.4
protective immunogen are under the negative control of Treg
during BCG immunization.
Figure 2. Effect of anti-CD25 mAb treatment on Treg compart-
ment and on anti-mycobacterial Th1 responses. (A) Mice
received, at days 22 and 11, i.p. injections of PBS or of 1 mg of the
control rat IgG (CRL-1912) or of anti-CD25 mAb (PC61). At day 0, mice
were immunized s.c. with 1610
6 CFU of BCG. (B) At day 21, percentages
of FoxP3
+ cells within CD4
+ T cell splenocytes were determined. Results
represent mean6SD obtained in individually studied mice (n=3).
*=statistically significant, as determined by Anova test, p,0.001. (C)
Frequency of IFN-c producing T splenocytes in response to TB10.3 or
TB10.4 in mice immunized by BCG and treated with anti-CD25 mAb. At
day 21 post-immunization, serial dilutions of splenocytes from mice
(n=6), unvaccinated or immunized with BCG and injected with PBS,
control IgG or PC61 mAb, as described in (A), were stimulated in vitro
with 10 mg/ml of TB10.3:74–88 (left) or TB10.4:74–88 (right) to
determine the frequency of specific CD4
+ IFN-c-producing T cells by
ELISPOT. Horizontal bars and the boxes indicate the mean values and
SD, respectively. Whiskers show the smallest and the largest values. * or
**=statistically significant, as determined by Student’s t test, p,0.02 or
0.01, respectively. Ns=no significant difference.
doi:10.1371/journal.pone.0002833.g002
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mycobacterial CD8
+ T-cell responses in BCG-immunized
mice
Based on the demonstration that Treg are able to down-regulate
CD8
+ T cell responses in immunization against Listeria monocyto-
genes in mouse model [29], we evaluated CD8
+ T-cell responses of
BCG-immunized BALB/c mice, injected with PBS, the control
IgG or anti-CD25 mAb, as shown in the Figure 2A. At day 21,
splenocytes from individual mice were stimulated with TB10.3/
4:20–28 peptide, containing a MHC-I-restricted epitope. The
frequency of specific T cells within CD8
+ T-cell population was
determined, as shown in Figure 4A, by use of a combination of
anti-CD8, anti-CD44 mAbs and a H-2K
d pentamer complexed
with the homologous peptide [30,31]. We observed that,
compared to the control groups, the anti-CD25 treatment of
BCG-immunized mice, slightly but not significantly, increased the
percentage of TB10.3/4:20–28-specific CD8
+ T cells in the
responding mice and did not improve the frequency of mice with
detectable TB10.3/4:20–28-specific CD8
+ T cells (Figure 4B).
Accordingly, in the numerous experiments that we performed to
evaluate anti-mycobacterial CD8
+ T-cell responses specific to
Ag85A or TB10.3/4, using either the
51Cr release cytotoxicity
assay or the MHC-I pentamer FACS assay, we always detected
only 30 to 50% of positive mice in BCG-immunized groups with
large variability in percentages of anti-mycobacterial CD8
+ T cells
among individuals of the same experimental group [30, data not
shown].
Recruitment/expansion of Treg in lung parenchyma of M.
tuberculosis-infected mice
To investigate the recruitment/expansion of Treg subset at the
site of M. tuberculosis infection, we infected BALB/c mice with <100
CFU of M. tuberculosis H37Rv by aerosol route. Similar to the
draining lymph nodes of BCG-immunized mice, following a 4-
week-kinetics study of the lung parenchyma, despite the constant
percentage of CD25
+ FoxP3
+ cells (Figure 5A), and CD25
2 FoxP3
+
within the CD4
+ T-cell subset the absolute number of these cells
statistically increased in the infected mice (Figure 5B), in parallel to
the well-characterized increase in the total number of lymphocytes
or of CD4
+ T cells recovered from the infected lungs [32].
Study of Th1 responses in anti-CD25-treated, BCG-
immunized and M. tuberculosis-infected mice
We then wondered whether, in the conditions of BCG
vaccination, Treg exert any inhibitory effect on the induction or
on the action of T cell-responses, responsible of the partial control
of subsequent M. tuberculosis challenge. To address this issue
BALB/c mice received, at days 22, 12 and 26, i.p. injections of
PBS, of control IgG or of anti-CD25 mAb (Figure 6A). At day 0,
mice were immunized s.c. with 1610
6 CFU of BCG. At day 30, all
groups were challenged by < 100 CFU/mouse of M. tuberculosis
H37Rv by aerosol route.
We analyzed anti-mycobacterial T-cell responses in these
experimental groups. Antigen-experienced CD4
+ T cells accumulat-
ing within mycobacteria-infected lung parenchyma can be divided
into CD27
+ and CD27
2 subsets. Only the CD27
2 population
contains highly differentiated, IFN-c-producing T cells [33]. Thus,
determination of percentages of activated CD27
2 cells represents an
appropriate way to measure Th1 response at the site of mycobacterial
infection. At one month post-challenge, we detected a markedly
increased percentage of CD45RB
2 CD27
2 cells within the CD4
+ T-
cell subset of mice infected with M. tuberculosis,c o m p a r e dt ot h e
untreated controls (Figure 6B). However, immunization with BCG or
treatment with the control IgG or anti-CD25 mAb did not modifythe
Figure 3. Effect of anti-CD25 mAb treatment on Th1 responses to immunodominant or subdominant regions of TB10.4
immunogen. Effect of anti-CD25 mAb treatment on Treg anti-mycobacterial Th1 responses to 15-mer overlapping peptides covering the entire
sequence of TB10.4. Mice were treated with the control rat IgG (CRL-1912) (A) or with anti-CD25 mAb (PC61) (B) as described in Figure 2A. At day 21,
splenocytes from individual mice were stimulated in vitro with 20 mg/ml of individual 15-mer overlapping peptides covering the entire sequence of
TB10.4. IFN-c secretion in the culture supernatant was assessed by ELISA at 72 h. Three mice were individually studied per experimental group and
one representative individual is shown.
doi:10.1371/journal.pone.0002833.g003
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2 CD27
2 cells within the lung CD4
+ T
subset of M. tuberculosis-infected mice. Moreover, the frequencies of
IFN-c-producing CD4
+ T cells from spleen or lungs, in response to
stimulation with PPD or immunodominant epitopes of TB10.4 or
Ag85A, were comparable in BCG-immunized and M. tuberculosis-
infected mice that were injected with PBS, the control IgG or anti-
CD25 mAb (data not shown). No difference was observed in the
TB10.3/4:20–28-specific CD8
+ T cell responses in these experimen-
tal groups (data not shown). Taken together, our results show that,
although the attenuation of Treg function increases the anti-
mycobacterial Th1 responses subsequent to BCG immunization
and at the time of the challenge and at the chronic phase of the
infection, the T-cell responses are comparable in all these
experimental groups, presumably due to the sustained level of
mycobacterial load and the consequent continuous T-cell triggering.
Anti-CD25 mAb treatment improves moderately but
significantly the protective effect of BCG vaccination
against infection with M. tuberculosis
It has been already shown that anti-CD25 mAb (PC61)
treatment has no consequence on the control of mycobacterial
growth in the lungs, neither at early, nor at late time points after
primary M. tuberculosis infection [15]. We thus focused on the effect
of anti-CD25 mAb treatment on the control of M. tuberculosis
infection subsequent to BCG immunization. We determined the
mycobacterial load in the lungs of mice either non-immunized or
immunized with BCG and treated with PBS, control IgG or anti-
CD25 mAb, and challenged with M. tuberculosis, as detailed in
Figure 6A. BCG immunization decreased the mycobacterial load
by 2 log10 (Figure 7). Anti-CD25 mAb treatment, concomitant to
BCG immunization, reproducibly led to a moderate, albeit
statistically significant, decrease of mycobacterial load at the site
of infection, i.e., the lung parenchyma (Figure 7, Experiments 1
and 2). In the experiment 1, the Mean6SD of the lung M.
tuberculosis load in BCG-immunized mice, injected with the control
IgG or anti-CD25 mAb was, respectively (1.9961.7)610
6 and
(0.4560.40)610
6, which means 4.4 fold less in the latter group. In
the experiment 2, the mycobacterial load in BCG-immunized
mice, injected with the control IgG or anti-CD25 mAb was,
respectively (2.061.0)610
5 and (1.060.9)610
5 which means 2
fold less in the latter. Importantly, 5 out of 9 individuals in the last
group displayed less than 1610
5 CFU/lungs. StatXact program
and permutation test (two-sided p-value) applied on the results
obtained from the experiments 1 and 2 showed that the differences
between the anti-CD25 mAb-treated mice and non-Ig-treated or
the control Ig-treated mice were statistically significant
(p,0.0420).
It is noteworthy that based on our long experience, in BCG-
immunized mice, the intensity of T-cell responses is of large
variability among the individual of the same experimental group.
In contrast, such variability was not observed in mice immunized
by a single mycobacterial protein (TB10.4 or ESAT-6) in adjuvant.
Figure 4. CD8
+ T-cell responses in anti-CD25 mAb treated,
BCG-immunized mice. (A) Representative CD8
+ T-cell response to
TB10.3 or TB10.4 in BALB/c mice immunized by BCG compared to
control non-immunized mice. At day 21 post-immunization, spleno-
cytes were stimulated in vitro with 10 mg/ml of TB10.3/4:20–28,
containing a H-2K
d-restricted immunodominant epitope. Six days later,
splenocytes were stained with a combination of FITC-anti-CD8,
allophycocyanine-anti-CD44 and PE-conjugated H-2K
d pentamer com-
plexed with TB10.3/4:20–28 peptide. Cells were then analyzed by
cytofluorometry. (B) Comparison of CD8
+ T-cell response to TB10.3 or
TB10.4 in individual mice, injected with PBS, the control IgG or PC61
mAb and immunized with BCG, as described in the Figure 2.
Percentages of pentamer
+ CD44
+ cells within the CD8
+ T-cell
population are shown in individual mice. Results are pooled from two
independent experiments. Ns, no significant difference as determined
by Student’s t test.
doi:10.1371/journal.pone.0002833.g004
Figure 5. Analysis of CD25
+ FoxP3
+ T cells in the lung
parenchyma of M. tuberculosis-infected mice. (A) Percentages of
CD25
+ FoxP3
+ cells within the CD4
+ T-cell subset in lung parenchyma of
untreated controls or of mice infected with <100 CFU of H37Rv by
aerosol route and (B) number of CD4
+ CD25
+ FoxP3
+ cells, in the lung
parenchyma of control or M. tuberculosis-infected mice. Results are
means6SD of three mice, studied individually. *, statistically significant
(Student’s t test, p,0.02).
doi:10.1371/journal.pone.0002833.g005
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BCG-immunized groups reflects the variability in cell-mediated
immune responses in different BCG-immunized individuals.
It is noteworthy that like C57BL/6 mice, BALB/c mice of
specific pathogen free status, neither die nor display morbidity,
even at 9 months following low dose H37Rv aerosol challenge.
Therefore, a possible benefic effect of Treg attenuation during
BCG immunization on M. tuberculosis–induced host mortality
cannot be evaluated in mouse experimental model. Histopatho-
logical analyses showed that the anti-CD25 treatment in mice
immunized with BCG and then infected with M. tuberculosis did not
lead to enhanced inflammation or exacerbated lung tissue damage
(data not shown). This indicates that dampening the anti-
inflammatory Treg subset by anti-CD25 mAb treatment did not
increase the inflammation due to mycobacterial infection. These
results show that the intervention of Treg, following BCG
immunization, contributes partly in limitation of the efficiency of
this vaccination in anti-mycobacterial protection.
Discussion
In the present study, we examined whether a recruitment/
expansion of Treg, concomitant to the induction of anti-
mycobacterial T-cell responses, could limit the efficiency of BCG
vaccine against infection with M. tuberculosis in mice. We first
observed that, during the four weeks following s.c. immunization
with BCG, despite the fact that the percentages of CD25
+ FoxP3
+
cells within the CD4
+ subset remains constant, the total number of
these cells increases proportionally to that of the other cells in the
inguinal draining lymph nodes, but not in the spleen. The same
holds true for the total number of Treg in the lung parenchyma of
mice infected with M. tuberculosis via the aerosol route. These
observations are in accordance with the data published by Quinn
et al. in which mice, infected with 1610
4 CFU of BCG by nasal
route or with <100 CFU of M. tuberculosis by aerosol route,
displayed increased size of the Treg compartment, proportional to
that of the other lymphocyte subsets [15]. As mentioned in the
Results, the increase of the Treg population in these cases may be
due to their recruitment, local proliferation/retention or conver-
sion from other CD4
+ T cells. It is noteworthy that the attenuated
BCG, inducer of weak infiltration and inflammation, or virulent
and highly persistent M. tuberculosis, both induce recruitment/
expansion of Treg, while one should expect that virulent
mycobacteria would elicit more efficient induction of Treg to
avoid tissue injury. This may suggest that induction of Treg is not
a consequence of inflammation.
In this study, our approach to evaluate the effect of Treg on
anti-mycobacterial adaptive immunity and protection was based
on the use of anti-CD25 mAb (PC61) treatment. This strategy has
Figure 6. Effect of anti-CD25 mAb treatment on CD4
+ T cells of
BCG-immunized, M. tuberculosis-infected mice. (A) Protocol of i.p.
anti-CD25 (PC61) mAb injections, s.c. BCG immunization, aerosol M.
tuberculosis challenge and of study of T cell functions and mycobac-
terial load in the lung parenchyma of BALB/c mice. (B) Activated/
effector CD4
+ T cells in the lung parenchyma of these mice. At one
month post-challenge, pooled lymphocytes from lung parenchyma of
each experimental group were stained with a combination of
allophycocyanine-anti-CD4, FITC-anti-CD45RB and PE-anti-CD27 mAbs
and analyzed by cytofluorometry.
doi:10.1371/journal.pone.0002833.g006
Figure 7. Effect of the attenuation of Treg on the protective
capacity of BCG. Evaluation of the protective capacity of BCG in mice
treated with anti-CD25 mAb, and challenged with M. tuberculosis,
performed as shown in Figure 6A. At one month post-challenge,
mycobacterial load in the lungs of mice was determined by CFU
counting. The number of CFU/lungs at day 1 post-challenge was
between 100 and 200 in the experiment 1, and between 10 and 100 in
the experiment 2. Horizontal bars and the vertical bars indicate the
mean values and SD, respectively. Two independents experiments were
performed and data from both of them were taken in account in
statistical analyses performed by use of StatXact program and
Permutation test. Ns=not significant, *, ** or ***=statistically
significant with two-sided p-value ,0.0420, 0.0046 or 0.0001, respec-
tively.
doi:10.1371/journal.pone.0002833.g007
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total depletion of this cell subset [19–21], in large numbers of
various experimental models, including those studying T-cell
responses to immunizations, to infections with virus, bacteria and
parasites, as well as in anti-tumor immune responses [19,22–24].
In most cases, the T-cell effector functions increase, suggesting that
the effect of PC61 treatment is more pronounced on Treg cells —
with great majority expressing high levels of CD25 — than on the
action of recently activated CD4
+ T-cell effectors — which
transiently express intermediary levels of CD25. Accordingly, the
fact that the PC61 treatment does not totally deplete the CD25
+
T-cell population and that IL2 is not the major or the only one
cytokine involved in the activation of CD4
+ T-cell effectors may
explain how PC61 treatment allows attenuation of Treg rather
than inhibition of effector functions. Furthermore, the effect of
PC61 treatment is relatively persistent, i.e., 12–15 days post-
injection [19–21], making this treatment adaptable to the long
experiments of anti-tuberculosis vaccination. At last, long-lasting
total depletion of Treg leads to lymphoproliferative disorders
[34,35], which can interfere with the adaptive responses mounted
against M. tuberculosis.
In mice immunized with BCG and treated by anti-CD25 mAb
(PC61), the frequency of IFN-c producing CD4
+ T cells specific to
the immunodominant epitopes of TB10.3 or TB10.4 immunogens
increased significantly. Attenuation of Treg subset by PC61
treatment increased the intensity of IFN-c responses to all
immunodominant and subdominant regions of TB10.4 antigen.
Barely immunogenic regions in IgG control-treated, BCG
immunized mice, become inducers of easily detectable IFN-c
responses in their PC61-treated counterparts. No new immuno-
genic regions were revealed under the conditions of Treg
attenuation, showing that the repertoire of T cells specific to the
different epitopes of TB10.4 is not modified quantitatively. Hence,
increase in T-cell responses to subdominant regions may have a
direct positive impact on anti-mycobacterial immune-protection,
as adaptive immune system becomes able to sense these epitopes
more sensitively. Note that TB10.3 and TB10.4 belong to the
highly immunogenic ESAT-6 protein family [25] and that TB10.4
is a powerful protective immunogen against M. tuberculosis infection
[26,27]. Only a weak and not significant, effect of anti-CD25 mAb
treatment was detected on the intensity of CD8
+ T-cell responses
specific to TB10.3 or TB10.4 immunogens, as judged by
determination of percentages of such cells by the use of a
pentamer of H-2K
d restricting element combined with TB10.3/
4:20–28 peptide [30,31].
We then studied the effect of anti-CD25 treatment on the control
of the growth of virulent M. tuberculosis H37Rv in mice immunized
with BCG. In accordance with previous reports [19–21], we
observed that after injection of anti-CD25 mAb (PC61), the
percentage of CD25
+ FoxP3
+ cells within the CD4
+ subset remains
decreased, as long as 2 weeks post injection, while at 4 weeks after
injection, the Treg subset was totally reconstituted. Based on these
data, we performed the anti-CD25 treatment regimen, shown in
Figure 6A, to obtain an attenuated Treg compartment: (i) at the
time of BCG injection, when anti-mycobacterial T-cell responses
are initiated, (ii) during the month following this immunization,
when anti-mycobacterial T cells expand, (iii) at the time of M.
tuberculosis challenge, when the induced anti-mycobacterial T cells
encounter the first infected cells, and (iv) at the beginning of the
virulence phase of the infection, when the action of such cells
controls,at leastpartially,thegrowthofmycobacteria.Therefore,in
this study, although at 1 month after the challenge, i.e., at day 34
after the last anti-CD25 mAb injection, the Treg subset has been
entirely recovered, the phases of initiation, expansion and effector
function of anti-mycobacterial T cells occurred under effective
attenuation of the Treg compartment. At 1 month post-challenge,
when mice possessed substantial mycobacterial load, Th1 responses
at the site of infection and in the spleen were comparable in all M.
tuberculosis-challenged mice,independentlyofBCGimmunization or
anti-CD25 mAb treatment. Our most important finding is that the
attenuation of Treg subset, by anti-CD25 mAb treatment,
concomitant to BCG immunization, moderately but significantly
improves the protective efficiency of this vaccine against infection
with virulent M. tuberculosis. Indeed, BCG-immunized, anti-CD25
treated mice, challenged with virulent H37Rv by aerosol route,
displayed a significantly reduced mycobacterial load at the site of
infection, compared to their counterparts immunized with BCG
aloneorimmunized with BCGandtreatedwitha control Igisotype.
Three different strategies have been already used to address the
role of Treg in mycobacterial infection. (i) Quinn et al. showed that
anti-CD25 mAb treatment during the early primary infection of
mice with mycobacteria, given by nasal route, increased
production of Th1 cytokines but did not reduce the mycobacterial
load in the lungs [15]. (ii) Kursar et al. showed that, co-transfer of
CD4
+ CD25
+ T cells with CD4
+ CD25
2 T cells, at a 1:2 ratio, i.e.,
markedly higher than the physiological ratio, into RAG1%
C57BL/6 mice, drastically decreased the capacity of CD4
+
CD25
2 T cells to control M. tuberculosis load in spleen and lungs.
Interestingly, the protective effect of CD4
+ CD25
2 T cells in this
model was not correlated with any increased IFN-c or TNF-a
responses [16]. (iii) More recently, Scott-Browne et al. set up a
mixed chimera C57BL/6 mouse model, reconstituted with bone-
marrow cells from Thy1.1 FoxP3
+/+ and Thy1.2 FoxP3% mice
[17]. In these chimeras, infection with M. tuberculosis by aerosol
route was better controlled when FoxP3
+ T cells were depleted by
anti-Thy-1.1 mAb treatment. Importantly, in this model, the total
depletion of Treg compartment induced a substantial polyclonal
stimulation of T-cell compartment but did not increase Th1
responses specific to mycobacterial antigens. Therefore, in that
study, it was not clear whether the cause of the improved control
of M. tuberculosis growth was the inhibition of the effect of Treg on
specific effector T cells, or a general bystander immuno-activation
effect [17]. These three experimental models are very different in
their detailed characteristics, yet in all of them, the mycobacterial
infection was given into non-vaccinated individuals and therefore
it was not evidenced whether prophylactic anti-mycobacterial
immunization with BCG gives rise to induction of Treg, able to
influence the outcome of the subsequent control of M. tuberculosis
infection. Our work directly addresses this question in the context
of a standard anti-tuberculosis vaccine assay and showed that the
efficient attenuation of Treg by PC61 mAb treatment, concom-
itant to BCG immunization, has a statistically significant, albeit
minor, effect on the fine tuning of T-cell immunity controlling M.
tuberculosis infection.
During the preparation of this manuscript, a first analysis of
anti-mycobacterial T-cell immunity and protection by BCG
immunization in Treg-attenuation conditions, prior to M.
tuberculosis challenge, has been published by Quinn et al [36]. This
team observed that functional attenuation of Treg by PC61 mAb
treatment during BCG vaccination increases Th1 responses to
Ag85A or to culture filtrate proteins of M. tuberculosis but not
protection against virulent M. bovis or M. tuberculosis. Compared to
this work performed on C57BL/6 mice [36], our study concerns
the effect of Treg in BALB/c mice immunized by BCG, in which
we were able to study both CD4
+ and CD8
+ T-cell responses to
TB10.3 and TB10.4 strong/protective immunogens. Moreover,
we characterized the Th1 responses to all the immunodominant
and subdominant regions of the TB10.4 antigen. By including
Treg in BCG immunization
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experiments, our work provides evidence that Treg influence the
immune control of M. tuberculosis infection.
Several major differences between our experimental conditions
and those of the work published by Quinn et al. [36] can explain the
different results obtained in these two investigations of the effect of
Treg on anti-mycobacterial protective capacity of BCG. Indeed,
both the pathogen and the host used in these two studies are
different. First M. tuberculosis Erdman strain has been used in the
study by Quinn et al. [36] versus M. tuberculosis H37Rv strain in the
presentstudy. As previously described [37], M. tuberculosisErdman is
less virulent than H37Rv in miceand therefore the characteristics of
mycobacterial infection are not comparable. Moreover, C57BL/6
mice have been used by Quinn et al versus BALB/c mice in the
present study. Importantly C57BL/6 and BALB/c mice are
genetically distant and therefore the characteristics of mycobacterial
infection, i.e., repertoire of T-cell responses, immunodominance of
mycobacterial antigens and H-2 restriction are distinct in these two
strains. Moreover, BALB/c strain is well known to develop more
readily Th2 responses while C57BL/6 mice are prototype of Th1-
proned mice. Most importantly, the frequency of Treg has been
suggested to be modulated by genetic background [38]. Indeed, this
studyshowsthatthefrequencyofCD4
+CD25
+T cellsinthethymus
and peripheral lymphoid organs of BALB/c mice is higher than in
C57BL/6 mice. Notably, CD4
+ responder T cells of BALB/c mice
show greater susceptibility to suppression of by Treg compare to
C57BL/6 mice [38]. Considering all these notable differences, one
cannot exclude that the effect of Treg on protective responses can
also be quantitatively and qualitatively different in BALB/c and
C57BL/6genetic backgrounds.Itis possiblethat BALB/c strainis a
more favorable animal model to detect the effect of Treg in Th1-
controlled infectious diseases like tuberculosis. Interestingly, the
pioneering work of Y. Belkaid et al describing the role of Treg in the
control of Leishmmania infection was done in BALB/c mice [13].
Based on our observations, during rational design of improved
BCG, it should be considered that, although the action of Treg
does not represent the major cause of the limited efficiency of
BCG, the impact of this regulatory cell population on the
subsequent control of M. tuberculosis growth is significant and
measurable. In contrast to the anti-CD25 mAb treatment, with
mild autoimmune manifestations, germline FoxP3 mutations or
general depletion of Treg performed in conditional FoxP3 mutants
leads to lymphadenopathy, extensive T-cell activation and severe
autoimmune lymphoproliferative disease in neonates and adults
[35,39]. Therefore, it would be of particular interest to evaluate
the control of M. tuberculosis, after BCG immunization, in an
experimental model closer to physiological conditions, for instance
under the action of TGF-b — which favors Treg development
[39] — or under the combined actions of TGF-b, IL-6 and IL-21,
detrimental to Treg development, yet favoring the development of
pro-inflammatory Th17 [40]. It has been suggested that the latter
can be involved in the recruitment of Th1 cells to the site of M.
tuberculosis infection [41], even though a direct role of IL-17 in the
control of M. tuberculosis growth remains to be confirmed [42].
Materials and Methods
Mice and Immunization
Female BALB/c mice were purchased from Charles Rivers
(Arbresle, France). Six—10-week-old mice received s.c. 1610
6
CFU of BCG per mouse. Animal studies were approved by the
Institut Pasteur Safety Committee in accordance with French and
European guidelines.
Mycobacteria
M. bovis BCG vaccine (Pasteur 1173P2) was kindly provided by
G. Marchal (Institut Pasteur, Paris). M. tuberculosis (H37Rv), was
grown at 37uC in Middlebrook 7H9 medium, complemented with
albumine, dextrose and catalase (ADC, Difco, Becton Dickinson,
Le Pont-de-Claix, France) and containing 0.05% Tween 80. All
experiments done with pathogenic M. tuberculosis were performed
in a P3 laboratory in accordance with the hygiene and security
recommendations of Institut Pasteur.
Peptides
TB10.3/4:20–28 [30], TB10.3:74–88 [43], TB10.4:74–88 [26],
Ag85A:101–120 [44] and PV1:103–116, derived from VP1
protein of type I poliovirus [45], used as a negative control, were
all synthetized by NeoMPS (Strasbourg, France).
Anti-CD25 in vivo treatment
Mice were injected i.p. with 0.5 or 1 mg of rat IgG1 anti-mouse
CD25 mAb (PC61) or of a control rat IgG1 (CRL-1912). These Ig
were prepared from ascitic fluids precipitated with 50%
(NH4)2SO4 at 4uC, in endotoxin-free conditions. Absence of
endotoxins in the Ig preparations was then checked by use of
‘‘Limulus Amebocytes Lysate’’ kit (Cambrex, Emerainville,
France), with a detection limit of 0.01 IU/ml.
CD4
+ T-cell assays
Anti-mycobacterial T-cell responses of immunized mice were
measured by IFN-c-specific ELISPOT, as previously described
[46]. Briefly, at day 21 after BCG immunization, serial dilutions of
splenocytes from individual mice were cultured for 36 hours in
synthetic HL-1 medium (BioWhittaker, Walkersville, MD) com-
plemented with 2 mM L-glutamax, 5610
25 M ß-mercapto-
ethanol, 100 IU penicillin/ml and 100 mg streptomycin/ml, in
the presence of 10 mg/ml of TB10.3:74–88, TB10.4:74–88 or a
negative control peptide, on anti-IFN-c mAb (R4-6A2)-coated 96-
well Multiscreen plates (Millipore, Saint-Quentin-en-Yvelines,
France). Biotinylated anti-IFN-c mAb (XMG1.2), alkaline phos-
phatase-conjugated streptavidin (PharMingen, Le Pont de Claix,
France) and 5-Bromo-5-Chloro-3-Indolyl Phosphate/Nitro‘‘Blue’’
Tetrazolium (Sigma), as phosphatase substrate, were used to reveal
the spots, automatically counted by use of a Bioreader-3000 Pro
(BIO-SYS, Karben, Germany). IFN-c responses in spleen of
individual BCG-immunized mice against TB10.4 pepscan,
containing 15-mer peptides synthesized in a single amino acid
step (Mimotopes, Clayton Victoria, Australia), were assessed as
previously described [26]. Briefly, splenoyctes from individual
mice were stimulated in vitro with 20 mg/ml of each peptide and
IFN-c production was assessed by ELISA after 72 h incubation.
CD8
+ T-cell assays
Three weeks after immunization with BCG, splenocytes from
mice were stimuled in vitro with 10 mg/ml of TB10.3/4:20–28
peptide [30] in RPMI complemented with 2 mM L-glutamax,
5610
25 M ß-mercapto-ethanol, 100 IU penicillin/ml and 100 mg
streptomycin/ml and 10% FCS. At day 6, detection of CD8
+ T
lymphocytes specific to TB10.3/4:20–28 epitope was performed
by cytofluorometry, by use of a PE-conjugated pentamer of H-
2K
d, complexed with TB10.3/4:20–28 peptide [31] (Proimmune,
Oxford, UK). We established that in this pentamer assay, in vitro
stimulation with TB10.3/4:20–28 peptide did not modify the
frequency of the responding mice, compared to ex vivo analysis.
Indeed, after in vitro stimulation, the percentages of the pentamer
+
cells increase in the same proportion in different individuals and
Treg in BCG immunization
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+ T cells
detected ex vivo. Therefore, following in vitro stimulation, the
sensitivity of this assay is improved without biasing the frequency
of the responding mice or the relative importance of CD8
+ T-cell
responses in different mice.
Preparation of lymphocytes from lung parenchyma
Lungs were perfused with type IV collagenase (400 U/ml) and
DNase I (Roche, Mannheim, Germany). After 45 min incubation
at 37uC, 5% CO2, lungs were homogenized and passed through
nylon filters with 100 mm-diameter pores (Cell Strainer, Becton,
Dickinson, Falcon). Cells were then enriched in lymphocytes on a
Ficoll gradient (Lympholyte M, Cedarlane Laboratories, Ontario
Canada) before cytofluorometric analyses.
Cytofluorometry
FITC-conjugated anti-CD8 (53–6.7), allophycocyanin-conju-
gated anti-CD44 (IM7), PE-conjugated anti-CD27 (LG.3A40) and
FITC-conjugated anti-CD45RB (16A) mAbs were all purchased
from PharMingen. Treg were detected by surface staining with
FITC-conjugated anti-CD4 (RM4-5) and allophycocyanin-conju-
gated anti-CD25 (PC61) mAbs, followed by fixation and
permeabilization by use of a mouse Treg staining kit (eBioscience,
San Diego, USA) and further intracellular staining with PE-
conjugated anti-FoxP3 (FJK16S) or a control isotype (eBioscience),
in the presence of FcR-blocking anti-CD16/32 mAb (2.4G2). Cells
from M. tuberculosis-infected mice were fixed by overnight
incubation with 4% paraformaldehyde at 4uC prior to their
analysis in a FacsCalibur system by use of CellQuest program
(Becton Dickinson Immunocytometry Systems, Mountain View,
CA, USA).
Protection assay against infection with M. tuberculosis
Mice were challenged, via the aerosol route, with M. tuberculosis
H37Rv, by use of a home-made nebulizor. Two ml of a suspension
containing 5610
6 CFU/ml were aerosolized to obtain an inhaled
dose of <100 CFU/mouse. Infected mice were placed in isolators.
One month post-challenge, lungs were homogenized by use of 2.5-
mm diameter glass beads and an MM300 organ homogenizer
(Qiagen, Courtaboeuf, France). Serial 5-fold dilutions of homoge-
nates were seeded on 7H11 Agar, supplemented with OADC (Difco,
Becton Dickinson, Sparks, MD). CFU were counted after 21 days of
incubation at 37uC. Two independents experiments were performed
and statistical analyses were performed by use of StatXact program
and Permutation test, as described previously [47].
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